Clementia Pharmaceuticals was a Montreal-based rare disease biopharmaceutical company founded in 2011. Its lead compound palovarotene, a retinoic acid receptor gamma agonist, was in clinical development for fibrodysplasia ossificans progressiva and multiple osteochondromas. Clementia was acquired by Ipsen in 2019 for approximately $1.3 billion.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account